Zanzalintinib for Metastatic Castration-Resistant Prostate Cancer

/in , , /by

Zanzalintinib is a new investigational drug showing activity in metastatic castrate-resistant prostate cancer (mCRPC), particularly in patients with soft tissue or visceral metastases who have progressed on prior treatment. A single-arm Phase II trial is evaluating whether zanzalintinib is effective for this difficult-to-treat population. Participants can stay in the study for up to 24 months […]

Read more

The MOMENT Trial: Mevrometostat Plus Enzalutamide in Post‑ARPI, Pre‑Abiraterone mCRPC

/in , , /by

Mevrometostat is an oral EZH2 inhibitor being developed to overcome resistance to androgen‑receptor–targeted therapy in prostate cancer. In tumors, EZH2 helps switch off tumor‑suppressor genes and supports androgen‑independent growth and lineage plasticity, changes that are strongly linked to progression on drugs like enzalutamide. Adding an EZH2 inhibitor to continued AR blockade is meant to “re‑discipline” […]

Read more

Phase 3 CaBRA Trial: Adding Carboplatin for mHSPC With BRCA Mutations or Neuroendocrine Phenotype

/in , , /by

In the phase 3 CaBRA trial, carboplatin is added to the docetaxel-based chemotherapy backbone used with lifelong ADT (androgen deprivation therapy) and darolutamide,  creating a quadruple-intensification  therapy for a small but very high-risk subgroup of metastatic castration-sensitive prostate cancer. The trial focuses on tumors with either BRCA alterations or neuroendocrine differentiation, two features that are […]

Read more

Scientists Identify SIRT1 as a Driver of Neuroendocrine Prostate Cancer

/in , /by

Researchers have identified SIRT1 as a promising new target in neuroendocrine prostate cancer, a rare but highly aggressive subtype that often develops after standard hormone therapy stops working. The finding is important because this form of prostate cancer is especially hard to treat and tends to behave more aggressively than typical androgen-driven disease. The study […]

Read more

B7-H3 ADC YL201 Delivers Encouraging Results in Advanced mCRPC

/in , , /by

YL201, a B7-H3–targeting antibody–drug conjugate, is showing notable activity in advanced metastatic castration-resistant prostate cancer (mCRPC), including patients who have progressed after androgen receptor–targeted therapy and chemotherapy. In a phase 2 study of 82 heavily pretreated patients, the drug delivered a confirmed PSA50 response rate of 38.5%, an objective response rate of 29.5%, and a […]

Read more

Phase 1/2 Trial: Epigenetic KAT6 Inhibitor Plus Darolutamide in mCRPC

/in , , , /by

A Phase 1b/2 trial is planned to test the investigational KAT6 inhibitor OP-3136 combined with darolutamide in metastatic castration-resistant prostate cancer (mCRPC). About 36 patients will be enrolled, with the study expected to start in the second half of 2026. The focus is on safety, tolerability, and early signs of anti-tumor activity. OP-3136 blocks KAT6A/B, […]

Read more

A-DREAM Trial Suggests Some Men with Metastatic Prostate Cancer May Stop Therapy Safely for a Time

/in , , /by

A new phase 2 study, A-DREAM / Alliance A032101, suggests that a carefully selected group of men with metastatic hormone-sensitive prostate cancer may be able to interrupt androgen deprivation therapy and an androgen receptor pathway inhibitor after achieving an excellent response, while still maintaining a treatment-free interval. The study met its primary endpoint, with 41% […]

Read more

Phase 2 TALENT Trial: Talazoparib as Monotherapy or With Enzalutamide in HRR-deficient mCRPC

/in , , /by

The TALENT trial is a randomized, open‑label, phase 2 trial evaluating whether adding enzalutamide to talazoparib improves outcomes compared with talazoparib alone in men with metastatic castration‑resistant prostate cancer (mCRPC) who have homologous recombination repair (HRR) gene alterations and have progressed after abiraterone‑based therapy. The trial builds on the phase 3 TALAPRO‑2 results, which showed […]

Read more